MORPHOSYS AG O.N.

Open:	-
Change:	-
Volume:	-

Low:	-
High:	-
High / Low range:	-

Type:	Stocks
Ticker:	MOR
ISIN:	DE0006632003

DGAP-News: MorphoSys To Participate in UBS Global Healthcare Conference

DGAP-News: MorphoSys AG / Key word(s): Conference
MorphoSys To Participate in UBS Global Healthcare Conference

21.05.2021 / 15:00
The issuer is solely responsible for the content of this announcement.

Media Release
Planegg/Munich, Germany, May 21, 2021

MorphoSys To Participate in UBS Global Healthcare Conference

MorphoSys AG (FSE & NASDAQ: MOR) today announced that Jean-Paul Kress, M.D., the company's Chief Executive Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday May 25, 2021 at 7:00 a.m. Eastern Time.

Live audio of the fireside chat can be accessed from the Media and Investors section under Conferences on MorphoSys' website, www.morphosys.com. A replay of the webcast will also be available on MorphoSys' website.

About MorphoSys
MorphoSys (FSE & NASDAQ: MOR) is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases. Based on its leading expertise in antibody and protein technologies, MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies which are developed by partners in different areas of unmet medical need. In 2017, Tremfya^(R)(guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the treatment of plaque psoriasis - became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval of MorphoSys' proprietary product Monjuvi^(R) (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma.

Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has more than 600 employees. More information at www.morphosys.com or www.morphosys-us.com.

Monjuvi^(R) is a registered trademark of MorphoSys AG.
Tremfya^(R) is a registered trademark of Janssen Biotech, Inc.

For more information, please contact:


Media Contacts: Thomas Biegi Vice President Tel.: +49 (0)89 / 89927 26079 [email protected]	Investor Contacts: Dr. Julia Neugebauer Senior Director Tel: +49 (0)89 / 899 27 179 [email protected]
Jeanette Bressi Director, US Communications Tel: +1 617-404-7816 [email protected]	Myles Clouston Senior Director Tel: +1 857-772-0240 [email protected]

21.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:	English
Company:	MorphoSys AG
	Semmelweisstr. 7
	82152 Planegg
	Germany
Phone:	+49 (0)89 899 27-0
Fax:	+49 (0)89 899 27-222
E-mail:	[email protected]
Internet:	www.morphosys.com
ISIN:	DE0006632003
WKN:	663200
Indices:	MDAX, TecDAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq
EQS News ID:	1199495


End of News	DGAP News Service

1199495 21.05.2021

EQS Group

EQS Group is a leading international technology provider for Digital Investor Relations, Corporate Communications and Compliance. More than 8,000 companies worldwide trust EQS’s products and services to securely, efficiently, and simultaneously fulfil complex national and international disclosure and compliance requirements, and to reach stakeholders globally.

Lastest analyses : MORPHOSYS AG O.N.